Price Alert

Ascendis Pharma A/S (ASND)

NASDAQ: ASND · Real-Time Price · USD

194.90

2.86 (1.49%)

At close: Aug 15, 2025, 1:04 PM

Ascendis Pharma A/S Statistics

Share Statistics

Ascendis Pharma A/S has 60.37M shares outstanding. The number of shares has increased by 5.27% in one year.

Shares Outstanding	60.37M
Shares Change (YoY)	5.27%
Shares Change (QoQ)	0.89%
Owned by Institutions (%)	99.99%
Shares Floating	60.12M
Failed to Deliver (FTD) Shares	229
FTD / Avg. Volume	0.05%

Short Selling Information

The latest short interest is 2.73M, so 4.51% of the outstanding shares have been sold short.

Short Interest	2.73M
Short % of Shares Out	4.51%
Short % of Float	5.42%
Short Ratio (days to cover)	6.11

Valuation Ratios

The PE ratio is -20.36 and the forward PE ratio is 86.66. Ascendis Pharma A/S's PEG ratio is 0.86.

PE Ratio	-20.36
Forward PE	86.66
PS Ratio	21.17
Forward PS	8.2
PB Ratio	-72.81
P/FCF Ratio	-25.02
PEG Ratio	0.86

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ascendis Pharma A/S.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.17, with a Debt / Equity ratio of -8.1.

Current Ratio	1.17
Quick Ratio	0.84
Debt / Equity	-8.1
Debt / EBITDA	-2.95
Debt / FCF	-2.78
Interest Coverage	-4.26

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$357.56K
Profits Per Employee	$-371.76K
Employee Count	1,017
Asset Turnover	0.31
Inventory Turnover	0.15

Taxes

Income Tax	4.84M
Effective Tax Rate	-1.3%

Stock Price Statistics

The stock price has increased by 52.51% in the last 52 weeks. The beta is 0.4, so Ascendis Pharma A/S's price volatility has been higher than the market average.

Beta	0.4
52-Week Price Change	52.51%
50-Day Moving Average	173.66
200-Day Moving Average	150.42
Relative Strength Index (RSI)	68.1
Average Volume (20 Days)	458,064

Income Statement

In the last 12 months, Ascendis Pharma A/S had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.

Revenue	363.64M
Gross Profit	319.38M
Operating Income	-278.76M
Net Income	-378.08M
EBITDA	-290.02M
EBIT	-307.74M
Earnings Per Share (EPS)	-6.53

Full Income Statement

Balance Sheet

The company has 559.54M in cash and 856.62M in debt, giving a net cash position of -297.07M.

Cash & Cash Equivalents	559.54M
Total Debt	856.62M
Net Cash	-297.07M
Retained Earnings	n/a
Total Assets	1.06B
Working Capital	35.98M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -306.2M and capital expenditures -1.43M, giving a free cash flow of -307.62M.

Operating Cash Flow	-306.2M
Capital Expenditures	-1.43M
Free Cash Flow	-307.62M
FCF Per Share	-5.31

Full Cash Flow Statement

Margins

Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.

Gross Margin	87.83%
Operating Margin	-76.66%
Pretax Margin	-102.64%
Profit Margin	-103.97%
EBITDA Margin	-79.76%
EBIT Margin	-76.66%
FCF Margin	-84.6%

Dividends & Yields

ASND does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for ASND is $230, which is 17.4% higher than the current price. The consensus rating is "Buy".

Price Target	$230
Price Target Difference	17.4%
Analyst Consensus	Buy
Analyst Count	15

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	5.16
Piotroski F-Score	2